Resolution of adipose tissue inflammation

TheScientificWorldJournal

Volumn 10, Issue , 2010, Pages 832-856

  González Périz, Ana ^a   Clària, Joan ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Adipocytes; Adiponectin; Adipose tissue; AMPK; Inflammation; Insulin signaling; Macrophages; Omega 3 PUFA; Omega 3 PUFA derived lipid autacoids; Protectins; Resolvins

Indexed keywords

ADIPONECTIN; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; AUTACOID; CD59 ANTIGEN; CHEMERIN; CHEMOATTRACTANT; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOPENTENONE DERIVATIVE; CYCLOPENTENONE PROSTAGLANDIN; FATTY ACID DERIVATIVE; INSULIN; INTERLEUKIN 10; INTERLEUKIN 6; LEPTIN; LEUKOTRIENE B4; LIPOXIN A; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OMEGA 3 FATTY ACID; PROSTAGLANDIN DERIVATIVE; REGULATOR PROTEIN; RESISTIN; RESOLVIN D1; RESOLVIN E1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANTIINFLAMMATORY ACTIVITY; CELL INFILTRATION; HUMAN; INFLAMMATION; INSULIN RESISTANCE; MEDIATOR RELEASE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

ADIPOKINES; ADIPOSE TISSUE; ANIMALS; FATTY ACIDS, OMEGA-3; FATTY ACIDS, OMEGA-6; HUMANS; INFLAMMATION;

EID: 77953448663     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2010.77     Document Type: Review

References (188)

1. Cannon, B. and Nedergaard, J. (2004) Brown adipose tissue: function and physiological significance. Physiol. Rev. 84, 277-359. (Pubitemid 38054374)
2. Redinger, R.N. (2009) Fat storage and the biology of energy expenditure. Transl. Res. 154, 52-60.
3. Guilherme, A., Virbasius, J.V., Puri, V., and Czech, M.P. (2008) Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat. Rev. Mol. Cell. Biol. 9, 367-377. (Pubitemid 351574198)
4. Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., and Friedman, J.M. (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425-432. (Pubitemid 24365442)
5. Hotamisligil, G.S., Shargill, N.S., and Spiegelman, B.M. (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259, 87-91.
6. Myers, M.G., Cowley, M.A., and Münzberg, H. (2008) Mechanisms of leptin action and leptin resistance. Annu. Rev. Physiol. 70, 537-556.
7. Ingalls, A.M., Dickie, M.M., and Snell, G.D. (1950) Obese, a new mutation in the house mouse. J. Hered. 41, 317-318.
8. La Cava, A., Alviggi, C., and Matarese, G. (2004) Unraveling the multiple roles of leptin in inflammation and autoimmunity. J. Mol. Med. 82, 4-11. (Pubitemid 38168097)
9. Loffreda, S., Yang, S.Q., Lin, H.Z., Karp, C.L., Brengman, M.L., Wang, D.J., Klein, A.S., Bulkley, G.B., Bao, C., Noble, P.W., Lane, M.D., and Diehl, A.M. (1998) Leptin regulates proinflammatory immune responses. FASEB J. 12, 57-65.
10. Chandra, R.K. (1980) Cell-mediated immunity in genetically obese C57BL/6J (ob/ob) mice. Am. J. Clin. Nutr. 33, 13-16. (Pubitemid 10141673)
11. Mandel, M.A. and Mahmoud, A.A. (1978) Impairment of cell-mediated immunity in mutation diabetic mice (db/db). J. Immunol. 120, 1375-1377.
12. Locksley, R.M., Killeen, N., and Lenardo, M.J. (2001) The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104, 487-501. (Pubitemid 32201945)
13. Tacke, F., Luedde, T., and Trautwein, C. (2009) Inflammatory pathways in liver homeostasis and liver injury. Clin. Rev. Allergy Immunol. 36, 4-12.
14. Tilg, H. and Moschen, A.R. (2006) Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat. Rev. Immunol. 6, 772-783. (Pubitemid 44453463)
15. Marra, F. and Bertolani, C. (2009) Adipokines in liver diseases. Hepatology 50, 957-969.
16. Streetz, K.L., Luedde, T., Manns, M.P., and Trautwein, C. (2000) Interleukin 6 and liver regeneration. Gut 47, 309-312.
17. Ramadori, G., Van Damme, J., Rieder, H., and Meyer zum Büschenfelde, K.H. (1988) Interleukin 6, the third mediator of acute-phase reaction, modulates hepatic protein synthesis in human and mouse. Comparison with interleukin 1 beta and tumor necrosis factor-alpha. Eur. J. Immunol. 18, 1259-1264.
18. Kanda, H., Tateya, S., Tamori, Y., Kotani, K., Hiasa, K., Kitazawa, R., Kitazawa, S., Miyachi, H., Maeda, S., Egashira, K., and Kasuga, M. (2006) MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J. Clin. Invest. 116, 1494-1505.
19. Bruun, J.M., Lihn, A.S., Pedersen, S.B., and Richelsen, B. (2005) Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): implication of macrophages resident in the AT. J. Clin. Endocrinol. Metab. 90, 2282-2289.
20. Maury, E. and Brichard, S.M. (2010) Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol. Cell. Endocrinol. 314, 1-16.
21. Steppan, C.M., Bailey, S.T., Bhat, S., Brown, E.J., Banerjee, R.R., Wright, C.M., Patel, H.R., Ahima, R.S., and Lazar, M.A. (2001) The hormone resistin links obesity to diabetes. Nature 409, 307-312. (Pubitemid 32151228)
22. Samal, B., Sun, Y., Stearns, G., Xie, C., Suggs, S., and McNiece, I. (1994) Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol. Cell. Biol. 14, 1431-1437.
23. Kadowaki, T. and Yamauchi, T. (2005) Adiponectin and adiponectin receptors. Endocr. Rev. 26, 439-451.
24. Hu, E., Liang, P., and Spiegelman, B.M. (1996) AdipoQ is a novel adipose-specific gene dysregulated in obesity. J. Biol. Chem. 271, 10697-10703. (Pubitemid 26145805)
25. Yamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M., Kita, S., Ueki, K., Eto, K., Akanuma, Y., Froguel, P., Foufelle, F., Ferre, P., Carling, D., Kimura, S., Nagai, R., Kahn, B.B., and Kadowaki, T. (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 8, 1288-1295.
26. van Exel, E., Gussekloo, J., de Craen, A.J., Frölich, M., Bootsma-Van Der Wiel, A., and Westendorp, R.G. (2002) Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes : the Leiden 85-Plus Study. Diabetes 51,1088-1092. (Pubitemid 34438354)
27. Straczkowski, M., Kowalska, I., Nikolajuk, A., Krukowska, A., and Gorska, M. (2005) Plasma interleukin-10 concentration is positively related to insulin sensitivity in young healthy individuals. Diabetes Care 28, 2036-2037. (Pubitemid 41060983)
28. Goralski, K.B., McCarthy, T.C., Hanniman, E.A., Zabel, B.A., Butcher, E.C., Parlee, S.D., Muruganandan, S., and Sinal, C.J. (2007) Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J. Biol. Chem. 282, 28175-28188.
29. Cash, J.L., Hart, R., Russ, A., Dixon, J.P., Colledge, W.H., Doran, J., Hendrick, A.G., Carlton, M.B., and Greaves, D.R. (2008) Synthetic chemerin-derived peptides suppress inflammation through ChemR23. J. Exp. Med. 205, 767-775.
30. Bozaoglu, K., Bolton, K., McMillan, J., Zimmet, P., Jowett, J., Collier, G., Walder, K., and Segal, D. (2007) Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 148, 4687-4694. (Pubitemid 47481514)
31. Trayhurn, P. (2005) Endocrine and signalling role of adipose tissue: new perspectives on fat. Acta Physiol. Scand. 184, 285-293.
32. Shoelson, S.E., Lee, J., and Goldfine, A.B. (2006) Inflammation and insulin resistance. J. Clin. Invest. 116, 1793-1801.
33. Trayhurn, P. and Wood, I.S. (2005) Signalling role of adipose tissue: adipokines and inflammation in obesity. Biochem. Soc. Trans. 33, 1078-1081. (Pubitemid 41659117)
34. Ferrante, A.W., Jr. (2007) Obesity-induced inflammation: a metabolic dialogue in the language of inflammation. J. Intern. Med. 262, 408-414.
35. Cancello, R., Henegar, C., Viguerie, N., Taleb, S., Poitou, C., Rouault, C., Coupaye, M., Pelloux, V., Hugol, D., Bouillot, J.L., Bouloumié, A., Barbatelli, G., Cinti, S., Svensson, P.A., Barsh, G.S., Zucker, J.D., Basdevant, A., Langin, D., and Clément, K. (2005) Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 54, 2277-2286.
36. Lumeng, C.N., Bodzin, J.L., and Saltiel, A.R. (2007) Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest. 117, 175-184.
37. Nishimura, S., Manabe, I., Nagasaki, M., Eto, K., Yamashita, H., Ohsugi, M., Otsu, M., Hara, K., Ueki, K., Sugiura, S., Yoshimura, K., Kadowaki, T., and Nagai, R. (2009) CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat. Med. 15, 914-920.
38. Winer, S., Chan, Y., Paltser, G., Truong, D., Tsui, H., Bahrami, J., Dorfman, R., Wang, Y., Zielenski, J., Mastronardi, F., Maezawa, Y., Drucker, D.J., Engleman, E., Winer, D., and Dosch, H.M. (2009) Normalization of obesity-associated insulin resistance through immunotherapy. Nat. Med. 15, 921-929.
39. Feuerer, M., Herrero, L., Cipolletta, D., Naaz, A., Wong, J., Nayer, A., Lee, J., Goldfine, A.B., Benoist, C., Shoelson, S., and Mathis, D. (2009) Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat. Med. 15, 930-939.
40. Furukawa, S., Fujita, T., Shimabukuro, M., Iwaki, M., Yamada, Y., Nakajima, Y., Nakayama, O., Makishima, M., Matsuda, M., and Shimomura, I. (2004) Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 114, 1752-1761.
41. Angulo, P. (2002) Nonalcoholic fatty liver disease. N. Engl. J. Med. 346, 1221-1231.
42. Sanyal, A.J. (2005) Mechanisms of disease: pathogenesis of nonalcoholic fatty liver disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2, 46-53. (Pubitemid 40812527)
43. Gastaldelli, A., Kozakova, M., Højlund, K., Flyvbjerg, A., Favuzzi, A., Mitrakou, A., and Balkau, B.; The RISC Investigators (2009) Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 49, 1537-1544.
44. Sanyal, A.J. (2002) AGA technical review on non-alcoholic fatty liver disease. Gastroenterology 123, 1705-1725. (Pubitemid 35231670)
45. Ginsberg, H.N. (2006) Is the slippery slope from steatosis to steatohepatitis paved with triglyceride or cholesterol? Cell Metab. 4, 179-181.
46. Tilg, H. and Moschen, A.R. (2008) Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol. Metab. 19, 371-379.
47. Pérez-Chacón, G., Astudillo, A.M., Balgoma, D., Balboa, M.A., and Balsinde, J. (2009) Control of free arachidonic acid levels by phospholipases A(2) and lysophospholipid acyltransferases. Biochim. Biophys. Acta 1791, 1103-1113.
48. Romano, M. and Clària, J. (2003) Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. FASEB J. 17, 1986-1995. (Pubitemid 37392443)
49. Dudzinski, D.M. and Serhan, C.N. (2004) Pharmacology of eicosanoids. In Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. Golan, D.E., Tashjian, A.H., Armstrong, E.J., Galanter, J.M., Armstrong, A.W., Arnaout, R.A., and Rose, H.S., Eds. Lippincott Williams & Wilkins, Philadelphia. pp. 627-646.
50. Clària, J. (2003) Cyclooxygenase-2 biology. Curr. Pharm. Des. 9, 2177-2190.
51. Morita, I. (2002) Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat. 68-69, 165-175.
52. Herschman, H.R. (1996) Prostaglandin synthase 2. Biochim. Biophys. Acta 1299, 125-140.
53. Smith, W.L. and Song, I. (2002) The enzymology of prostaglandin endoperoxide H synthases-1 and -2. Prostaglandins Other Lipid Mediat. 68-69, 115-128.
54. Jakobsson, P.J., Thoren, S., Morgenstern, R., and Samuelsson, B. (1999) Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc. Natl. Acad. Sci. U. S. A. 96, 7220-7225.
55. Shaw, J.E. and Ramwell, P.W. (1968) Release of prostaglandin from rat epididymal fat pad on nervous and hormonal stimulation. J. Biol. Chem. 243, 1498-1503.
56. Chatzipanteli, K., Rudolph, S., and Axelrod, L. (1992) Coordinate control of lipolysis by prostaglandin E2 and prostacyclin in rat adipose tissue. Diabetes 41, 927-935.
57. Richelsen, B. (1987) Factors regulating the production of prostaglandin E2 and prostacyclin (prostaglandin I2) in rat and human adipocytes. Biochem. J. 247, 389-394.
58. Richelsen, B., Børglum, J.D., and Sørensen, S.S. (1992) Biosynthetic capacity and regulatory aspects of prostaglandin E2 formation in adipocytes. Mol. Cell. Endocrinol. 85, 73-81.
59. Richelsen, B. (1992) Release and effects of prostaglandins in adipose tissue. Prostaglandins Leukot. Essent. Fatty Acids 47, 171-182.
60. 2, prostacyclin and leptin release by human adipocytes versus explants of adipose tissue in primary culture. Prostaglandins Leukot. Essent. Fatty Acids 67, 467-473.
61. Aubert, J., Saint-Marc, P., Belmonte, N., Dani, C., Négrel, R., and Ailhaud, G. (2000) Prostacyclin IP receptor up-regulates the early expression of C/EBPbeta and C/EBPdelta in preadipose cells. Mol. Cell. Endocrinol. 160, 149-156. (Pubitemid 30129061)
62. Forman, B.M., Tontonoz, P., Chen, J., Brun, R.P., Spiegelman, B.M., and Evans, R.M. (1995) 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83, 803-812.
63. Reginato, M.J., Krakow, S.L., Bailey, S.T., and Lazar, M.A. (1998) Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 273, 1855-1858.
64. Vassaux, G., Gaillard, D., Ailhaud, G., and Négrel, R. (1992) Prostacyclin is a specific effector of adipose cell differentiation. Its dual role as a cAMP- and Ca(2+)-elevating agent. J. Biol. Chem. 267, 11092-11097.
65. Fain, J.N., Leffler, C.W., Cowan, G.S., Jr., Buffington, C., Pouncey, L., and Bahouth, S.W. (2001) Stimulation of leptin release by arachidonic acid and prostaglandin E(2) in adipose tissue from obese humans. Metabolism 50, 921-928.
66. Jaworski, K., Ahmadian, M., Duncan, R.E., Sarkadi-Nagy, E., Varady, K.A., Hellerstein, M.K., Lee, H.Y., Samuel, V.T., Shulman, G.I., Kim, K.H., de Val, S., Kang, C., and Sul, H.S. (2009) AdPLA ablation increases lipolysis and prevents obesity induced by high-fat feeding or leptin deficiency. Nat. Med. 15, 159-168.
67. Basu, S. (2007) Novel cyclooxygenase-catalyzed bioactive prostaglandin F2alpha from physiology to new principles in inflammation. Med. Res. Rev. 27, 435-468.
68. Fajas, L., Miard, S., Briggs, M.R., and Auwerx, J. (2003) Selective cyclo-oxygenase-2 inhibitors impair adipocyte differentiation through inhibition of the clonal expansion phase. J. Lipid Res. 44, 1652-1659. (Pubitemid 37185875)
69. Yan, H., Kermouni, A., Abdel-Hafez, M., and Lau, D.C. (2003) Role of cyclooxygenases COX-1 and COX-2 in modulating adipogenesis in 3T3-L1 cells. J. Lipid Res. 44, 424-429. (Pubitemid 37287786)
70. Hsieh, P.S., Jin, J.S., Chiang, C.F., Chan, P.C., Chen, C.H., and Shih, K.C. (2009) COX-2-mediated inflammation in fat is crucial for obesity-linked insulin resistance and fatty liver. Obesity 17, 1150-1157.
71. Lijnen, H.R., Van Hoef, B., Lu, H.R., and Gallacher, D.J. (2008) Rofecoxib impairs adipose tissue development in a murine model of nutritionally induced obesity. Thromb. Haemost. 100, 338-342.
72. Fain, J.N., Ballou, L.R., and Bahouth, S.W. (2001) Obesity is induced in mice heterozygous for cyclooxygenase-2. Prostaglandins Other Lipid Mediat. 65, 199-209.
73. Rådmark, O. (2002) Arachidonate 5-lipoxygenase. Prostaglandins Other Lipid Mediat. 68-69, 211-234.
74. Funk, C.D., Hoshiko, S., Matsumoto, T., Rådmark, O., and Samuelsson, B. (1989) Characterization of the human 5-lipoxygenase gene. Proc. Natl. Acad. Sci. U. S. A. 86, 2587-2591.
75. Samuelsson, B., Dahlen, S.E., Lindgren, J.A., Rouzer, C.A., and Serhan, C.N. (1987) Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 237, 1171-1176.
76. Borgeat, P., Hamberg, M., and Samuelsson, B. (1976) Transformation of arachidonic acid and homo-gamma-linolenic acid by rabbit polymorphonuclear leukocytes. Monohydroxy acids from novel lipoxygenases. J. Biol. Chem. 251, 7816-7820. (Pubitemid 8015793)
77. Dixon, R.A., Diehl, R.E., Opas, E., Rands, E., Vickers, P.J., Evans, J.F., Gillard, J.W., and Miller, D.K. (1990) Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 343, 282-284.
78. Funk, C.D. (2001) Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294, 1871-1875.
79. Horrillo, R., González-Périz, A., Martínez-Clemente, M., López-Parra, M., Ferré, N., Titos, E., Morán-Salvador, E., Deulofeu, R., Arroyo, V., and Clària, J. (2010) 5-Lipoxygenase activating protein signals adipose tissue inflammation and lipid dysfunction in experimental obesity. J. Immunol. 184, 3978-3987.
80. Bäck, M., Sultan, A., Ovchinnikova, O., and Hansson, G.K. (2007) 5-Lipoxygenase-activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation. Circ. Res. 100, 946-949.
81. Kaaman, M., Rydén, M., Axelsson, T., Nordström, E., Sicard, A., Bouloumié, A., Langin, D., Arner, P., and Dahlman, I. (2006) ALOX5AP expression, but not gene haplotypes, is associated with obesity and insulin resistance. Int. J. Obes. (Lond.) 30, 447-452.
82. Funk, C.D. (1996) The molecular biology of mammalian lipoxygenases and the quest for eicosanoid functions using lipoxygenase-deficient mice. Biochim. Biophys. Acta 1304, 65-84.
83. Chakrabarti, S.K., Cole, B.K., Wen, Y., Keller, S.R., and Nadler, J.L. (2009) 12/15-Lipoxygenase products induce inflammation and impair insulin signaling in 3T3-L1 adipocytes. Obesity (Silver Spring) 17, 1657-1663.
84. González-Périz, A., Horrillo, R., Ferré, N., Gronert, K., Dong, B., Morán-Salvador, E., Titos, E., Martínez-Clemente, M., López-Parra, M., Arroyo, V., and Clària, J. (2009) Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J. 23, 1946-1957.
85. Madsen, L., Petersen, R.K., Sørensen, M.B., Jørgensen, C., Hallenborg, P., Pridal, L., Fleckner, J., Amri, E.Z., Krieg, P., Furstenberger, G., Berge, R.K., and Kristiansen, K. (2003) Adipocyte differentiation of 3T3-L1 preadipocytes is dependent on lipoxygenase activity during the initial stages of the differentiation process. Biochem. J. 375, 539-549.
86. Sears, D.D., Miles, P.D., Chapman, J., Ofrecio, J.M., Almazan, F., Thapar, D., and Miller, Y.I. (2009) 12/15-Lipoxygenase is required for the early onset of high fat diet-induced adipose tissue inflammation and insulin resistance in mice. PloS One 4, e7250.
87. Nunemaker, C.S., Chen, M., Pei, H., Kimble, S.D., Séller, S.R., Carter, J.D., Yang, Z., Smith, K.M., Wu, R., Bevard, M.H., Garmey, J.C., and Nadler, J.L. (2008) 12-Lipoxygenase-knockout mice are resistant to inflammatory effects of obesity induced by Western diet. Am. J. Physiol. Endocrinol. Metab. 295, E1065-1075.
88. Perretti, M. and D'Acquisto, F. (2009) Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat. Rev. Immunol. 9, 62-70.
89. Serhan, C.N., Brain, S.D., Buckley, C.D., Gilroy, D.W., Haslett, C., O'Neill, L.A., Perretti, M., Rossi, A.G., and Wallace, J.L. (2007) Resolution of inflammation: state of the art, definitions and terms. FASEB J. 21, 325-332. (Pubitemid 46213480)
90. Lawrence, T., Willoughby, D.A., and Gilroy, D.W. (2002) Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat. Rev. Immunol. 2, 787-795. (Pubitemid 37328718)
91. Kohli, P. and Levy, B.D. (2009) Resolvins and protectins: mediating solutions to inflammation. Br. J. Pharmacol. 158, 960-971.
92. Levy, B.D., Clish, C.B., Schmidt, B., Gronert, K., and Serhan, C.N. (2001) Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol. 2, 612-619. (Pubitemid 32677628)
93. Serhan, C.N., Chiang, N., and Van Dyke, T.E. (2008) Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 8, 349-361. (Pubitemid 351595216)
94. Chiang, N., Arita, M., and Serhan, C.N. (2005) Anti-inflammatory circuitry: lipoxin, aspirin-triggered lipoxins and their receptor ALX. Prostaglandins Leukot. Essent. Fatty Acids 73, 163-177.
95. Marcus, A.J. (1986) Transcellular metabolism of eicosanoids. Prog. Hemost. Thromb. 8, 127-142.
96. Romano, M. (2010) Lipoxins and aspirin-triggered lipoxins. TheScientificWorldJOURNAL 10, 1048-1064.
97. Serhan, C.N. and Sheppard, K.A. (1990) Lipoxin formation during human neutrophil-platelet interactions. Evidence for the transformation of leukotriene A4 by platelet 12-lipoxygenase in vitro. J. Clin. Invest. 85, 772-780.
98. Serhan, C.N. and Romano, M. (1995) Lipoxin biosynthesis and actions: role of the human platelet LX-synthase. J. Lipid Mediat. Cell Signal. 12, 293-306.
99. Serhan, C.N., Hamberg, M., and Samuelsson, B. (1984) Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc. Natl. Acad. Sci. U. S. A. 81, 5335-5339. (Pubitemid 14048742)
100. Clària, J., Lee, M.H., and Serhan, C.N. (1996) Aspirin-triggered lipoxins (15-epi-LX) are generated by the human lung adenocarcinoma cell line (A549)-neutrophil interactions and are potent inhibitors of cell proliferation. Mol. Med. 2, 583-596. (Pubitemid 26353107)
101. Bannenberg, G.L., Chiang, N., Ariel, A., Arita, M., Tjonahen, E., Gotlinger, K.H., Hong, S., and Serhan, C.N. (2005) Molecular circuits of resolution: formation and actions of resolvins and protectins. J. Immunol. 174, 4345-4355. (Pubitemid 40396017)
102. Chavis, C., Vachier, I., Chanez, P., Bousquet, J., and Godard, P. (1996) 5(S),15(S)-Dihydroxyeicosatetraenoic acid and lipoxin generation in human polymorphonuclear cells: dual specificity of 5-lipoxygenase towards endogenous and exogenous precursors. J. Exp. Med. 183, 1633-1643. (Pubitemid 26134305)
103. Clària, J., Titos, E., Jiménez, W., Ros, J., Ginès, P., Arroyo, V., Rivera, F., and Rodés, J. (1998) Altered biosynthesis of leukotrienes and lipoxins and host defense disorders in patients with liver cirrhosis. Gastroenterology 115, 147-156.
104. Clària, J. and Serhan, C.N. (1995) Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc. Natl. Acad. Sci. U. S. A. 92, 9475-9479.
105. Lee, T.H., Horton, C.E., Kyan-Aung, U., Haskard, D., Crea, A.E., and Spur, B.W. (1989) Lipoxin A4 and lipoxin B4 inhibit chemotactic responses of human neutrophils stimulated by leukotriene B4 and N-formyl-L-methionyl-Lleucyl- L-phenylalanine. Clin. Sci. 77, 195-203.
106. Colgan, S.P., Serhan, C.N., Parkos, C.A., Delp-Archer, C., and Madara, J.L. (1993) Lipoxin A4 modulates transmigration of human neutrophils across intestinal epithelial monolayers. J. Clin. Invest. 92, 75-82.
107. Papayianni, A., Serhan, C.N., and Brady, H.R. (1996) Lipoxin A4 and B4 inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells. J. Immunol. 56, 2264-2272.
108. Gronert, K., Gewirtz, A., Madara, J.L., and Serhan, C.N. (1998) Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon gamma and inhibits tumor necrosis factor alpha-induced IL-8 release. J. Exp. Med. 187, 1285-1294.
109. Hachicha, M., Pouliot, M., Petasis, N.A., and Serhan, C.N. (1999) Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1alpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis. J. Exp. Med. 189, 1923-1930.
110. 4. FASEB J. 16, 1937-1939.
111. Chiang, N., Gronert, K., Clish, C.B., O'Brien, J.A., Freeman, M.W., and Serhan, C.N. (1999) Leukotriene B4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. J. Clin. Invest. 104, 309-316.
112. Takano, T., Fiore, S., Maddox, J.F., Brady, H.R., Petasis, N.A., and Serhan, C.N. (1997) Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors. J. Exp. Med. 185, 693-704.
113. Godson, C., Mitchell, S., Harvey, K., Petasis, N.A., Hogg, N., and Brady, H.R. (2000) Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J. Immunol. 164, 1663-1667. (Pubitemid 30108713)
114. Scalia, R., Gefen, J., Petasis, N.A., Serhan, C.N., and Lefer, A.M. (1997) Lipoxin A4 stable analogs inhibit leukocyte rolling and adherence in the rat mesenteric microvasculature: role of P-selectin. Proc. Natl. Acad. Sci. U. S. A. 94, 9967-9972. (Pubitemid 27408174)
115. Takano, T., Clish, C.B., Gronert, K., Petasis, N.A., and Serhan, C.N. (1998) Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues. J. Clin. Invest. 101, 819-826. (Pubitemid 28096079)
116. Pouliot, M., Clish, C.B., Petasis, N.A., Van Dyke, T.E., and Serhan, C.N. (2000) Lipoxin A(4) analogues inhibit leukocyte recruitment to Porphyromonas gingivalis: a role for cyclooxygenase-2 and lipoxins in periodontal disease. Biochemistry 39, 4761-4768. (Pubitemid 30225341)
117. Van Dyke, T.E. and Serhan, C.N. (2003) Resolution of inflammation: a new paradigm for the pathogenesis of periodontal diseases. J. Dent. Res. 82, 82-90.
118. Levy, B.D., De Sanctis, G.T., Devchand, P.R., Kim, E., Ackerman, K., Schmidt, B.A., Szczeklik, W., Drazen, J.M., and Serhan, C.N. (2002) Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4). Nat. Med. 8, 1018-1023.
119. Karp, C.L., Flick, L.M., Park, K.W., Softic, S., Greer, T.M., Keledjian, R., Yang, R., Uddin, J., Guggino, W.B., Atabani, S.F., Belkaid, Y., Xu, Y., Whitsett, J.A., Accurso, F.J., Wills-Karp, M., and Petasis, N.A. (2004) Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat. Immunol. 5, 388-392.
120. Fiorucci, S., Wallace, J.L., Mencarelli, A., Distrutti, E., Rizzo, G., Farneti, S., Morelli, A., Tseng, J.L., Suramanyam, B., Guilford, W.J., and Parkinson, J.F. (2004) A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. Proc. Natl. Acad. Sci. U. S. A. 101, 15736-15741.
121. Bäck, M., Sultan, A., Ovchinnikova, O., and Hansson, G.K. (2007) 5-Lipoxygenase-activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation. Circ. Res. 100, 946-949. (Pubitemid 46598919)
122. Vaughn, M.W., Proske, R.J., and Haviland, D.L. (2002) Identification, cloning, and functional characterization of a murine lipoxin A4 receptor homologue gene. J. Immunol. 169, 3363-3369. (Pubitemid 35013186)
123. Straus, D.S. and Glass, C.K. (2001) Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med. Res. Rev. 21, 185-210.
124. 2 and the ligation of PPARgamma. J. Clin. Invest. 112, 945-955.
125. Gilroy, D.W., Colville-Nash, P.R., Willis, D., Chivers, J., Paul-Clark, M.J., and Willoughby, D.A. (1999) Inducible cyclooxygenase may have anti-inflammatory properties. Nat. Med. 5, 698-701. (Pubitemid 29289435)
126. Cernuda-Morollon, E., Pineda-Molina, E., Canada, F.J., and Perez-Sala, D. (2001) 15-Deoxy-delta 12,14-prostaglandin J2 inhibition of NF-kappaB-DNA binding through covalent modification of the p50 subunit. J. Biol. Chem. 276, 35530-35536.
127. Thieringer, R., Fenyk-Melody, J.E., Le Grand, C.B., Shelton, B.A., Detmers, P.A., Somers, E.P., Carbin, L., Moller, D.E., Wright, S.D., and Berger, J. (2000) Activation of peroxisome proliferator-activated receptor gamma does not inhibit IL-6 or TNF-alpha responses of macrophages to lipopolysaccharide in vitro or in vivo. J. Immunol. 164, 1046-1054. (Pubitemid 30043733)
128. Tsubouchi, Y., Kawahito, Y., Kohno, M., Inoue, K., Hla, T., and Sano, H. (2001) Feedback control of the arachidonate cascade in rheumatoid synoviocytes by 15-deoxy-delta(12,14)-prostaglandin J2. Biochem. Biophys. Res. Commun. 283, 750-755.
129. Quraishi, O., Mancini, J.A., and Riendeau, D. (2002) Inhibition of inducible prostaglandin E(2) synthase by 15-deoxy-delta(12,14)-prostaglandin J(2) and polyunsaturated fatty acids. Biochem. Pharmacol. 63, 1183-1189. (Pubitemid 34267034)
130. Planagumà, A., Clària, J., Miquel, R., López-Parra, M., Titos, E., Masferrer, J.L., Arroyo, V., and Rodés, J. (2005) The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPARgamma activation. FASEB J. 19, 1120-1122.
131. Bishop-Bailey, D. and Hla, T. (1999) Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-delta12, 14-prostaglandin J2. J. Biol. Chem. 274, 17042-17048.
132. 2 induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J. Clin. Invest. 106, 189-197.
133. Gilroy, D.W., Colville-Nash, P.R., McMaster, S., Sawatzky, D.A., Willoughby, D.A., and Lawrence, T. (2003) Inducible cyclooxygenase-derived 15- deoxy(delta)12-14PGJ2 brings about acute inflammatory resolution in rat pleurisy by inducing neutrophil and macrophage apoptosis. FASEB J. 17, 2269-2271. (Pubitemid 39561462)
134. Ward, C., Dransfield, I., Murray, J., Farrow, S.N., Haslett, C., and Rossi, A.G. (2002) Prostaglandin D2 and its metabolites induce caspase-dependent granulocyte apoptosis that is mediated via inhibition of I kappa B alpha degradation using a peroxisome proliferator-activated receptor-gamma-independent mechanism. J. Immunol. 168, 6232-6243.
135. Li, L., Tao, J., Davaille, J., Feral, C., Mallat, A., Rieusset, J., Vidal, H., and Lotersztajn, S. (2001) 15-Deoxy-delta 12,14-prostaglandin J2 induces apoptosis of human hepatic myofibroblasts. A pathway involving oxidative stress independently of peroxisome-proliferator-activated receptors. J. Biol. Chem. 276, 38152-38158.
136. Emi, M. and Maeyama, K. (2004) The biphasic effects of cyclopentenone prostaglandins, prostaglandin J(2) and 15-deoxy-delta(12,14)-prostaglandin J(2) on proliferation and apoptosis in rat basophilic leukemia (RBL-2H3) cells. Biochem. Pharmacol. 67, 1259-1267. (Pubitemid 38315091)
137. Kondo, M., Shibata, T., Kumagai, T., Osawa, T., Shibata, N., Kobayashi, M., Sasaki, S., Iwata, M., Noguchi, N., and Uchida, K. (2002) 15-Deoxy-delta(12,14)-prostaglandin J(2): the endogenous electrophile that induces neuronal apoptosis. Proc. Natl. Acad. Sci. U. S. A. 99, 7367-7372.
138. Castrillo, A., Traves, P.G., Martin-Sanz, P., Parkinson, S., Parker, P.J., and Bosca, L. (2003) Potentiation of protein kinase C zeta activity by 15-deoxy-delta(12,14)-prostaglandin J(2) induces an imbalance between mitogen-activated protein kinases and NF-kappa B that promotes apoptosis in macrophages. Mol. Cell. Biol. 23, 1196-1208.
139. Díez-Dacal, B. and Pérez-Sala, D. (2010) Anti-inflammatory prostanoids: focus on the interactions between electrophile signaling and resolution of inflammation. TheScientificWorldJOURNAL 10, 655-675.
140. Ding, Q., Mracek, T., Gonzalez-Muniesa, P., Kos, K., Wilding, J., Trayhurn, P., and Bing, C. (2009) Identification of macrophage inhibitory cytokine-1 in adipose tissue and its secretion as an adipokine by human adipocytes. Endocrinology 150, 1688-1696.
141. Sinha, D., Addya, S., Murer, E., and Boden, G. (1999) 15-Deoxy-delta(12,14) prostaglandin J2: a putative endogenous promoter of adipogenesis suppresses the ob gene. Metabolism 48, 786-791.
142. Calder, P.C. (2006) n-3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am. J. Clin. Nutr. 83, 1505S-1519S.
143. GISSI Researchers (1999) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 354, 447-455.
144. Mori, T.A., Bao, D.Q., Burke, V., Puddey, I.B., and Beilin, L.J. (1999) Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans. Hypertension 34, 253-260. (Pubitemid 29409224)
145. Harris, W.S. (1997) n-3 Fatty acids and serum lipoproteins: human studies. Am. J. Clin. Nutr. 65, 1645S-1654.
146. Kremer, J.M., Bigauoette, J., Michalek, A.V., Timchalk, M.A., Lininger, L., Rynes, R.I., Huyck, C., Zieminski, J., and Bartholomew, L.E. (1985) Effects of manipulation of dietary fatty acids on clinical manifestations of rheumatoid arthritis. Lancet 1, 184-187. (Pubitemid 15151457)
147. Bagga, D., Wang, L., Farias-Eisner, R., Glaspy, J.A., and Reddy, S.T. (2003) Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc. Natl. Acad. Sci. U. S. A. 100, 1751-1756. (Pubitemid 36254520)
148. Smith, W.L. (2005) Cyclooxygenases, peroxide tone and the allure of fish oil. Curr. Opin. Cell Biol. 17, 174-182.
149. Vecchini, A., Ceccarelli, V., Susta, F., Caligiana, P., Orvietani, P., Binaglia, L., Nocentini, G., Riccardi, C., Calviello, G., Palozza, P., Maggiano, N., and Di Nardo, P. (2004) Dietary alpha-linolenic acid reduces COX-2 expression and induces apoptosis of hepatoma cells. J. Lipid Res. 45, 308-316.
150. James, M.J., Gibson, R.A., and Cleland, L.G. (2000) Dietary polyunsaturated fatty acids and inflammatory mediator production. Am. J. Clin. Nutr. 71, 343S-348S.
151. Serhan, C.N., Clish, C.B., Brannon, J., Colgan, S.P., Chiang, N., and Gronert, K. (2000) Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J. Exp. Med. 192, 1197-1204.
152. Hong, S., Gronert, K., Devchand, P.R., Moussignac, R.L., and Serhan, C.N. (2003) Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J. Biol. Chem. 278, 14677-14687. (Pubitemid 36799790)
153. Serhan, C.N., Hong, S., Gronert, K., Colgan, S.P., Devchand, P.R., Mirick, G., and Moussignac, R.L. (2002) Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196, 1025-1037.
154. Serhan, C.N., Gotlinger, K., Hong, S., and Arita, M. (2004) Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis. Prostaglandins Other Lipid Mediat. 73, 155-172.
155. Serhan, C.N., Gotlinger, K., Hong, S., Lu, Y., Siegelman, J., Baer, T., Yang, R., Colgan, S.P., and Petasis, N.A. (2006) Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. J. Immunol. 176, 1848-1859.
156. Arita, M., Bianchini, F., Aliberti, J., Sher, A., Chiang, N., Hong, S., Yang, R., Petasis, N.A., and Serhan, C.N. (2005) Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J. Exp. Med. 201, 713-722.
157. Haas-Stapleton, E.J., Lu, Y., Hong, S., Arita, M., Favoreto, S., Nigam, S., Serhan, C.N., and Agabian, N. (2007) Candida albicans modulates host defense by biosynthesizing the pro-resolving mediator resolvin E1. PLoS One 2, e1316.
158. Marcheselli, V.L., Hong, S., Lukiw, W.J., Tian, X.H., Gronert, K., Musto, A., Hardy, M., Gimenez, J.M., Chiang, N., Serhan, C.N., and Bazan, N.G. (2003) Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J. Biol. Chem. 278, 43807-43817.
159. Serhan, C.N. (2007) Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu. Rev. Immunol. 25, 101-137.
160. Arita, M., Yoshida, M., Hong, S., Tjonahen, E., Glickman, J.N., Petasis, N.A., Blumberg, R.S., and Serhan, C.N. (2005) Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc. Natl. Acad. Sci. U. S. A. 102, 7671-7676.
161. Arita, M., Ohira, T., Sun, Y.P., Elangovan, S., Chiang, N., and Serhan, C.N. (2007) Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J. Immunol. 178, 3912-3917.
162. Bannenberg, G. (2010) Therapeutic applicability of anti-inflammatory and proresolving polyunsaturated fatty acid-derived lipid mediators. TheScientificWorldJOURNAL 10, 676-712.
163. Seki, H., Sasaki, T., Ueda, T., and Arita, M. (2010) Resolvins as regulators of the immune system. TheScientificWorldJOURNAL 10, 818-831.
164. Gronert, K., Maheshwari, N., Khan, N., Hassan, I.R., Dunn, M., and Laniado Schwartzman, M. (2005) A role for the mouse 12/15-lipoxygenase pathway in promoting epithelial wound healing and host defense. J. Biol. Chem. 280, 15267-15278.
165. González-Périz, A., Planagumà, A., Gronert, K., Miquel, R., López-Parra, M., Titos, E., Horrillo, R., Ferré, N., Deulofeu, R., Arroyo, V., Rodés, J., and Clària, J. (2006) Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA. FASEB J. 20, 2537-2539.
166. Ariel, A., Li, P.L., Wang, W., Tang, W.X., Fredman, G., Hong, S., Gotlinger, K.H., and Serhan, C.N. (2005) The docosatriene protectin D1 is produced by TH2 skewing and promotes human T cell apoptosis via lipid raft clustering. J. Biol. Chem. 280, 43079-43086.
167. Schwab, J.M., Chiang, N., Arita, M., and Serhan, C.N. (2007) Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447, 869-874.
168. Dona, M., Fredman, G., Schwab, J.M., Chiang, N., Arita, M., Goodarzi, A., Cheng, G., von Andrian, U.H., and Serhan, C.N. (2008) Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets. Blood 112, 848-855.
169. Mukherjee, P.K., Marcheselli, V.L., Serhan, C.N., and Bazan, N.G. (2004) Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc. Natl. Acad. Sci. U. S. A. 101, 8491-8496.
170. Levy, B.D., Kohli, P., Gotlinger, K., Haworth, O., Hong, S., Kazani, S., Israel, E., Haley, K.J., and Serhan, C.N. (2007) Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J. Immunol. 178, 496-502.
171. Haworth, O., Cernadas, M., Yang, R., Serhan, C.N., and Levy B.D. (2008) Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat. Immunol. 9, 873-879.
172. Spite, M., Norling, L.V., Summers, L., Yang, R., Cooper, D., Petasis, N.A., Flower, R.J., Perretti, M., and Serhan, C.N. (2009) Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 461, 1287-1291.
173. Krebs, J.D., Browning, L.M., McLean, N.K., Rothwell, J.L., Mishra, G.D., Moore, C.S., and Jebb, S.A. (2006) Additive benefits of long-chain n-3 polyunsaturated fatty acids and weight-loss in the management of cardiovascular disease risk in overweight hyperinsulinaemic women. Int. J. Obes. (Lond.) 30, 1535-1544.
174. Lundbom, J., Heikkinen, S., Fielding, B., Hakkarainen, A., Taskinen, M.R., and Lundbom, N. (2009) PRESS echo time behavior of triglyceride resonances at 1.5T: detecting omega-3 fatty acids in adipose tissue in vivo. J. Magn. Reson. 201, 39-47.
175. Pérez-Echarri, N., Pérez-Matute, P., Marcos-Gómez, B., Baena, M.J., Marti, A., Martínez, J.A., and Moreno-Aliaga, M.J. (2008) Differential inflammatory status in rats susceptible or resistant to diet-induced obesity: effects of EPA ethyl ester treatment. Eur. J. Nutr. 47, 380-386.
176. Kuda, O., Jelenik, T., Jilkova, Z., Flachs, P., Rossmeisl, M., Hensler, M., Kazdova, L., Ogston, N., Baranowski, M., Gorski, J., Janovska, P., Kus, V., Polak, J., Mohamed-Ali, V., Burcelin, R., Cinti, S., Bryhn, M., and Kopecky, J. (2009) n-3 Fatty acids and rosiglitazone improve insulin sensitivity through additive stimulatory effects on muscle glycogen synthesis in mice fed a high-fat diet. Diabetologia 52, 941-951.
177. Zeyda, M., Farmer, D., Todoric, J., Aszmann, O., Speiser, M., Györi, G., Zlabinger, G.J., and Stulnig, T.M. (2007) Human adipose tissue macrophages are of an anti-inflammatory phenotype but capable of excessive pro-inflammatory mediator production. Int. J. Obes. (Lond.) 31, 1420-1428.
178. Todoric, J., Löffler, M., Huber, J., Bilban, M., Reimers, M., Kadl, A., Zeyda, M., Waldhäusl, W., and Stulnig, T.M. (2006) Adipose tissue inflammation induced by high-fat diet in obese diabetic mice is prevented by n-3 polyunsaturated fatty acids. Diabetologia 49, 2109-2119.
179. Pachikian, B.D., Neyrinck, A.M., Cani, P.D., Portois, L., Deldicque, L., De Backer, F.C., Bindels, L.B., Sohet, F.M., Malaisse, W.J., Francaux, M., Carpentier, Y.A., and Delzenne, N.M. (2008) Hepatic steatosis in n-3 fatty acid depleted mice: focus on metabolic alterations related to tissue fatty acid composition. BMC Physiol. 8, 21.
180. Sener, A., Zhang, Y., Bulur, N., Louchami, K., Malaisse, W.J., and Carpentier, Y.A. (2009) The metabolic syndrome of omega3-depleted rats. II. Body weight, adipose tissue mass and glycemic homeostasis. Int. J. Mol. Med. 24, 125-129.
181. Ji, S., Hardy, R.W., and Wood, P.A. (2009) Transgenic expression of n-3 fatty acid desaturase (fat-1) in C57/BL6 mice: effects on glucose homeostasis and body weight. J. Cell. Biochem. 107, 809-817.
182. Glass, C.K. (2006) Going nuclear in metabolic and cardiovascular disease. J. Clin. Invest. 116, 556-522.
183. Semple, R.K., Chartejee, V.K., and O'Rahilly, S. (2006) PPAR gamma and human metabolic disease. J. Clin. Invest. 116, 581-589.
184. Yamamoto, K., Itoh, T., Abe, D., Shimizu, M., Kanda, T., Koyama, T., Nishikawa, M., Tamai, T., Ooizumi, H., and Yamada, S. (2005) Identification of putative metabolites of docosahexaenoic acid as potent PPARgamma agonists and antidiabetic agents. Bioorg. Med. Chem. Lett. 15, 517-522.
185. Long Y.C. and Zierath J.R. (2006) AMP-activated protein kinase signaling in metabolic regulation. J. Clin. Invest. 116, 1776-1783.
186. Nawrocki, A.R., Rajala, M.W., Tomas, E., Pajvani, U.B., Saha, A.K., Trumbauer, M.E., Pang, Z., Chen, A.S., Ruderman, N.B., Chen, H., Rossetti, L., and Scherer, P.E. (2006) Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J. Biol. Chem. 281, 2654-2660.
187. López-Parra, M., Titos, E., Horrillo, R., Ferré, N., González-Périz, A., Martínez-Clemente, M., Planagumà, A., Masferrer, J., Arroyo, V., and Clària, J. (2008) Regulatory effects of arachidonate 5-lipoxygenase on hepatic microsomal TG transfer protein activity and VLDL-triglyceride and apoB secretion in obese mice. J. Lipid Res. 49, 2513-2523.
188. Campbell, E.L., Louis, N.A., Tomassetti, S.E., Canny, G.O., Arita, M., Serhan, C.N., and Colgan, S.P. (2007) Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution. FASEB J. 21, 3162-3170. (Pubitemid 47565535)